Answer
Zanidatamab has an estimated elimination half-life of approximately 21 days in patients with biliary tract cancer receiving 20 mg/kg every 2 weeks at steady state, based on population pharmacokinetic analysis.
Sources for this answer
- Ziihera 300 mg powder for concentrate for solution for infusionJazz Pharmaceuticals Research UK Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 3Document updated
Sources checked